![]() |
![]() |
Your cart is empty |
||
Showing 1 - 2 of 2 matches in All Departments
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
|
![]() ![]() You may like...
United States Circuit Court of Appeals…
U S Court of Appeals Ninth Circuit
Hardcover
R831
Discovery Miles 8 310
Cyclin Dependent Kinase (CDK) Inhibitors
Peter K. Vogt, Stephen I. Reed
Paperback
R3,488
Discovery Miles 34 880
Nolo's Essential Guide to Buying Your…
Ilona Bray, Ann O'Connell
Paperback
Next Generation Antibody Drug Conjugates…
Ulf Grawunder, Stefan Barth
Hardcover
R5,352
Discovery Miles 53 520
Sugar Chains - Decoding the Functions of…
Tadashi Suzuki, Kazuaki Ohtsubo, …
Hardcover
R4,240
Discovery Miles 42 400
|